Skip to content
Screener

aTyr Pharma ATYR Total Liabilities & Equity

Total Liabilities & Equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$87.63B-7.4%
Merck & Co. logo
Merck & Co.MRK
$129.8B+10.4%
United Therapeutics logo
United TherapeuticsUTHR
$7.22B-8.7%
Rein Therapeutics Inc. logo
Rein Therapeutics Inc.RNTX
$26.29M-54.4%
CTO
Citius Oncology, Inc.CTOR
$100.7M+10.1%
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
$230.44M-3.0%

Other financials

Income statement

See full
Revenue-
Operating income-$10.9M+46.4%
Net income-$10.3M+47.2%
EPS (diluted)-$0.11+50.0%

Balance sheet

See full
Cash & equivalents$16.2M-6.2%
Total debt$11.8M-10.7%
Total equity$48.8M-34.8%
Total assets$69.8M-31.2%

Cash flow

See full
Operating cash flow-$9.4M+32.7%
CapEx$73.0K+711%
Free cash flow-$9.4M+32.2%

Valuation

See full
Market cap$50.14M-89.6%
Enterprise value$45.8M-90.4%

Profitability

See full
Operating margin-40,856.3%+28,833pp
Net margin-39,009.5%+29,653pp
FCF margin-32,664.7%+4,018pp

Returns & leverage

See full
Return on equity-98.4%+18.0pp
Debt / equity0.2×+0.1×
Current ratio5.1×-0.5×

Where this comes from

Reported directly by aTyr Pharma in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: aTyr Pharma’s 10-Q, filed August 7, 2026.

Filed
Aug 7, 2026, 4:07 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001339970-26-000053
Line itemJune 30, 2026December 31, 2025
Common stock, $0.001 par value per share; 340,000,000 and 170,000,000 authorized shares as of June 30, 2026 (unaudited) and December 31, 2025, respectively; 98,087,425 and 98,031,014 issued and outstanding shares as of June 30, 2026 (unaudited) and December 31, 2025, respectively9898
Additional paid-in capital676,022673,554
Accumulated other comprehensive loss(68)(8)
Accumulated deficit(627,264)(606,164)
Total aTyr Pharma, Inc. stockholders’ equity48,78867,480
Noncontrolling interest in Pangu BioPharma Limited(194)(192)
Total stockholders’ equity48,59467,288
Total liabilities and stockholders’ equity$69,825$93,003

Item 1. Financial Statements

FAQ

What is aTyr Pharma's total liabilities & equity?
aTyr Pharma (ATYR) reported total liabilities & equity of $69.83M in Q2 2026.
How has aTyr Pharma's total liabilities & equity changed year-over-year?
aTyr Pharma's total liabilities & equity decreased by 31.2% year-over-year, from $101.53M to $69.83M.
What is the long-term trend for aTyr Pharma's total liabilities & equity?
Over 5 years (2020 to 2025), aTyr Pharma's total liabilities & equity has grown at a 19.2% compound annual growth rate (CAGR), from $38.73M to $93M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about aTyr Pharma's total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude